Overview

Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease

Status:
Completed
Trial end date:
2020-03-03
Target enrollment:
Participant gender:
Summary
This is the first study in humans to evaluate the effectiveness of SJP-0132 in the treatment of dry eye disease. This study will evaluate the safety, tolerability, efficacy, and pharmacokinetics of single- and multiple-dose regimens of SJP-0132 in subjects with dry eye disease
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Senju Pharmaceutical Co., Ltd.